Design and activity analysis of chimeric epidermal growth factor fusion vaccine E5T-mSEA.
- Author:
Qingqing YIN
1
;
Haiwei JIA
;
Yanhong ZHANG
;
Chuanxuan LIU
;
Qingjun MA
;
Buchang ZHANG
;
Hui ZHONG
;
Quanbin XU
Author Information
1. Department of Life Science, Anhui University, Hefei 230039, China.
- Publication Type:Journal Article
- MeSH:
Amino Acid Sequence;
Animals;
Cancer Vaccines;
biosynthesis;
immunology;
Cell Line, Tumor;
Enterotoxins;
biosynthesis;
genetics;
Epidermal Growth Factor;
biosynthesis;
genetics;
Escherichia coli;
genetics;
metabolism;
Humans;
Immunization;
Mice;
Mice, Inbred C57BL;
Molecular Sequence Data;
Random Allocation;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors;
immunology;
Recombinant Fusion Proteins;
biosynthesis;
genetics;
immunology;
Transforming Growth Factor alpha;
biosynthesis;
genetics
- From:
Chinese Journal of Biotechnology
2010;26(3):357-362
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) and its ligands (EGF and TGFalpha) are over-expressed in a variety of tumors. Immunization EGF-carrier protein inhibits tumor growth through abrogating binding of EGF to EGFR. Here, a chimeric protein of EGF and TGFalpha (E5T) was genetically fused to Staphylococcal enterotoxin A (SEA), a bacterial superantigenic protein which promotes humoral B cell response through enhancement of Ag-specific CD4 T cells activity. The resulted fusion proteins were expressed in Escherichia coli and purified though metal chelating affinity chromatography. Immunization of E5T-mSEA fusion protein in mice induced production of high titers antibodies, which recognize both EGF and TGFalpha. Anti- E5T-mSEA serum at dilution of 1:10 significantly inhibited growth of A431 cell lines but had little effect on 293T cell lines.
